The TGA has approved a new treatment for asthma and COPD, while a new laxative has been released in Australia, and GSK has launched its new Nicabate Oral Strips.
New asthma/COPD treatment approved
The TGA has this week approved a new treatment for asthma and COPD.
BreoEllipta, manufactured by GSK Australia and Theravance, is a combination of the inhaled corticosteroid (ICS), fluticasone furoate, and the long-acting beta2-agonist (LABA), vilanterol.
Two strengths of Breo Ellipta have been